| Status: Partially superseded | |
Product meets AWMSG exclusion criteria due to NICE appraisal. TA341: Apixaban for the treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism |
|
Medicine details |
|
| Medicine name | apixaban (Eliquis®) |
| Formulation | 2.5 mg, 5 mg film-coated tablet |
| Reference number | 476 |
| Indication | Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults |
| Company | Bristol-Myers Squibb Pharmaceuticals Ltd/Pfizer Ltd |
| BNF chapter | Cardiovascular system |
| Submission type | N/A |
| Status | Partially superseded |
| Date of issue | 15/09/2014 |
| NICE guidance | |